Our Philadelphia Victoza drug injury lawyers are evaluating cases involving pancreatic cancer and other injuries in people who have used the type-2 diabetes drug Victoza. Victoza, a glucagonlike peptide 1 (GLP-1) receptor agonist manufactured by Novo Nordisk., is one of a class of drugs known as incretin mimetics.
Victoza has been associated with serious injuries, including:
- pancreatic cancer
- medullary thyroid cancer
- renal failure / kidney failure
- pancreatic duct metaplasia
- pancreatic hemorrhage
- wrongful death
Victoza and Pancreatic Cancer
An incretin mimetic works by mimicking the function of natural incretin hormones, which diabetics may release in insufficient quantities. Natural incretin hormones (or incretin mimetics, such as Victoza) stimulate the pancreas’s release of insulin to lower blood sugar. Victoza helps to reduce high blood sugar following a meal, but it may also increase a patient’s risk of pancreatic cancer.
Other incretin mimetic and incretin therapy drugs include:
- Januvia (see Philadelphia Januvia Drug Injury Lawyers)
- Janumet (see Philadelphia Janumet Drug Injury Lawyers)
- Byetta (see Philadelphia Byetta Drug Injury Lawyers)
- Bydureon (see Philadelphia Bydureon Drug Injury Lawyers)
- Onglyza (see Philadelphia Onglyza Drug Injury Lawyers)
- Janumet XR
Victoza FDA Warnings and Studies
The July 2011 issue of Gastroenterology reported results of a study showing a six-fold increase pancreatitis risk in users of dipeptidyl peptidase-4 (DPP-4) inhibitor and glucagonlike peptide 1 (GLP-1) receptor agonist incretin drug therapy. Study subjects also demonstrated an increased risk of pancreatic cancer.
On March 14, 2013, the U.S. Food and Drug Administration (FDA) published a drug safety communication warning of a potential risk increase for pancreatic cancer, pancreatitis, and pancreatic duct metaplasia following use of Victoza and similar drugs.
On April 8, 2013, the NIH (National Institutes of Health) reported results of a study showing a significantly increased risk of acute pancreatitis following treatment with DPP-4 inhibitor or glucagonlike peptide 1 (GLP-1) incretin therapy drugs. Study subjects also exhibited a 40% increase in pancreas size from use of Victoza or another incretin therapy.
A study reported in the New England Journal of Medicine (NEJM ) on July 28, 2016, showed more than double the number of pancreatic cancer cases in users of Victoza (liraglutide) than in subjects given placebo.
Lawsuits filed by Philadelphia Victoza drug injury lawyers may allege that Novo Nordisk:
- manufactured and sold an unreasonably dangerous and defective medication
- failed to conduct adequate pre-market safety and side effect tests before releasing Victoza to the marketplace
- failed to provide adequate warnings to physicians and consumers of the risks of pancreatic cancer and other dangerous side effects associated with Victoza
- engaged in false and aggressive advertising of a dangerous drug with knowledge of dangerous side effects
Contact our Philadelphia Victoza Drug Injury Lawyers
If you or a loved one developed pancreatic cancer or another serious injury after using the type-2 diabetes drug Victoza, you may be entitled to compensation from the manufacturer. Contact our Philadelphia Victoza drug injury lawyers, today, to inquire about the possibility of instituting a Victoza lawsuit.